董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard J. Roberts | 男 | Director | 79 | 5.80万美元 | 未持股 | 2023-12-05 |
| C. Ann Merrifield | 女 | Chairman of the Board | 72 | 8.74万美元 | 未持股 | 2023-12-05 |
| Christina Morrison | 女 | Director | 56 | 6.68万美元 | 未持股 | 2023-12-05 |
| Richard Toselli | 男 | President and Chief Executive Officer and Director | 66 | 96.00万美元 | 未持股 | 2023-12-05 |
| Robert J. Rosenthal | 男 | Director | 67 | 6.80万美元 | 未持股 | 2023-12-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Christopher | 男 | Chief Financial Officer | 53 | 58.38万美元 | 未持股 | 2023-12-05 |
| Richard Toselli | 男 | President and Chief Executive Officer and Director | 66 | 96.00万美元 | 未持股 | 2023-12-05 |
| Heather Hamel | 女 | Chief Legal Officer and General Counsel | 34 | 47.66万美元 | 未持股 | 2023-12-05 |
董事简历
中英对照 | 中文 | 英文- Richard J. Roberts
-
Richard J. Roberts自2010年10月起担任公司的董事，2008年11月起担任InVivo Therapeutics 公司（InVivo Therapeutics Corporation，Invivo Therapeutics Holdings Corp.全资拥有子公司）的董事。他在2007年6月首次加入InVivo Therapeutics公司（InVivo Therapeutics Corporation）的科学咨询董事会，并一直担任公司的科学咨询董事会的一员。他自2007年2月起担任New England Biolabs的首席科学家。他因为Phillip Allen Sharp进行真核基因内含子的发现及其基因剪接机制的研究而获得了1993年诺贝尔医学生理学奖。他拥有英国谢菲尔德大学（University of Sheffield, U.K）化学学士学位和有机化学博士学位。
Richard J. Roberts,has been a director of Invivo Therapeutics Holdings Corp. since October 2010 and a director of InVivo Therapeutics Corporation, Invivo Therapeutics Holdings Corp. wholly-owned subsidiary, since November 2008. Dr. Roberts initially joined InVivo Therapeutics Corporation's Scientific Advisory Board in June 2007 and continued as a member of Invivo Therapeutics Holdings Corp. Scientific Advisory Board. He has served as Chief Scientific Officer at New England Biolabs, a life sciences company, since February 2007. Dr. Roberts was awarded the 1993 Nobel Prize in Physiology of Medicine along with Phillip Allen Sharp for the discovery of introns in eukaryotic DNA and the mechanism of gene-splicing. He holds a B.Sc. in Chemistry and a Ph.D. in Organic Chemistry from the University of Sheffield, U.K. - Richard J. Roberts自2010年10月起担任公司的董事，2008年11月起担任InVivo Therapeutics 公司（InVivo Therapeutics Corporation，Invivo Therapeutics Holdings Corp.全资拥有子公司）的董事。他在2007年6月首次加入InVivo Therapeutics公司（InVivo Therapeutics Corporation）的科学咨询董事会，并一直担任公司的科学咨询董事会的一员。他自2007年2月起担任New England Biolabs的首席科学家。他因为Phillip Allen Sharp进行真核基因内含子的发现及其基因剪接机制的研究而获得了1993年诺贝尔医学生理学奖。他拥有英国谢菲尔德大学（University of Sheffield, U.K）化学学士学位和有机化学博士学位。
- Richard J. Roberts,has been a director of Invivo Therapeutics Holdings Corp. since October 2010 and a director of InVivo Therapeutics Corporation, Invivo Therapeutics Holdings Corp. wholly-owned subsidiary, since November 2008. Dr. Roberts initially joined InVivo Therapeutics Corporation's Scientific Advisory Board in June 2007 and continued as a member of Invivo Therapeutics Holdings Corp. Scientific Advisory Board. He has served as Chief Scientific Officer at New England Biolabs, a life sciences company, since February 2007. Dr. Roberts was awarded the 1993 Nobel Prize in Physiology of Medicine along with Phillip Allen Sharp for the discovery of introns in eukaryotic DNA and the mechanism of gene-splicing. He holds a B.Sc. in Chemistry and a Ph.D. in Organic Chemistry from the University of Sheffield, U.K.
- C. Ann Merrifield
-
C. Ann Merrifield自2014年起担任公司的董事。2012年12月-2014年7月她担任PathoGenetix股份有限公司（PathoGenetix, Inc，一家私人持股的健康技术公司）的总裁和首席执行官，2014年7月她自愿申请Chapter 7破产。在加入PathoGenetix股份有限公司（PathoGenetix, Inc）之前，她在Genzyme公司（Genzyme Corporation，现在被Sanofi S.A（一个多元化，全球生物技术公司）拥有）工作了18年。在Genzyme之前，她目前担任Genzyme Biosurgery的总裁，她领导着生物制剂，治疗设备和组合产品的投资的全球业务战略，先前是Genzyme Genetics的营销副总裁、总经理和总裁，扮演一个发展和塑造诊断业务的重要角色。在加入Genzyme之前，她是Bain and 公司（Bain and Company，一家全球战略咨询公司）的合伙人、Aetna Life & Casualty的投资官。她目前担任InVivo Therapeutics Holdings Corp（一家上市的生物技术公司）的董事，也是MassMutual Premier、Select and MML Series Investment Funds的受托人。她拥有缅因大学（University of Maine）动物学学士学位和教育硕士学位和达特茅斯学院阿摩司商学院（达特茅斯学院阿摩司商学院）工商管理硕士学位。
C. Ann Merrifield,has served as a member of Board since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector, which include InVivo Therapeutics Holdings Corp., from November 2014 until January 2025, and Flexion Therapeutics, Inc., from June 2014 to November 2021 until it was acquired by Pacira BioSciences. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, the Huntington Theatre Company, the YMCA of Greater Boston, and the International Institute of New England. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College. - C. Ann Merrifield自2014年起担任公司的董事。2012年12月-2014年7月她担任PathoGenetix股份有限公司（PathoGenetix, Inc，一家私人持股的健康技术公司）的总裁和首席执行官，2014年7月她自愿申请Chapter 7破产。在加入PathoGenetix股份有限公司（PathoGenetix, Inc）之前，她在Genzyme公司（Genzyme Corporation，现在被Sanofi S.A（一个多元化，全球生物技术公司）拥有）工作了18年。在Genzyme之前，她目前担任Genzyme Biosurgery的总裁，她领导着生物制剂，治疗设备和组合产品的投资的全球业务战略，先前是Genzyme Genetics的营销副总裁、总经理和总裁，扮演一个发展和塑造诊断业务的重要角色。在加入Genzyme之前，她是Bain and 公司（Bain and Company，一家全球战略咨询公司）的合伙人、Aetna Life & Casualty的投资官。她目前担任InVivo Therapeutics Holdings Corp（一家上市的生物技术公司）的董事，也是MassMutual Premier、Select and MML Series Investment Funds的受托人。她拥有缅因大学（University of Maine）动物学学士学位和教育硕士学位和达特茅斯学院阿摩司商学院（达特茅斯学院阿摩司商学院）工商管理硕士学位。
- C. Ann Merrifield,has served as a member of Board since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector, which include InVivo Therapeutics Holdings Corp., from November 2014 until January 2025, and Flexion Therapeutics, Inc., from June 2014 to November 2021 until it was acquired by Pacira BioSciences. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, the Huntington Theatre Company, the YMCA of Greater Boston, and the International Institute of New England. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College.
- Christina Morrison
-
Christina Morrison自2016年6月起担任公司董事。莫里森女士自2018年4月起担任门诊手术中心管理公司Physicians Endoscope的首席财务官。在此之前，Morrison女士于2013年6月至2016年7月担任Aramark（一家公开上市的食品服务，设施和制服服务提供商）财务高级副总裁。在加入ARAMARK之前，莫里森女士于2009年11月至2013年6月担任默克制药公司（一家公开上市的制药公司）业务和财务规划高级副总裁。在此之前，Morrison女士在惠氏制药公司（Wyeth Pharmaceuticals）工作了五年，该公司是一家公开上市的制药公司，担任过多个领导职务，包括制药部门的高级副总裁和首席财务官。Morrison女士拥有达特茅斯学院塔克商学院（Tuck School of Business at Dartmouth College）的工商管理硕士学位和宾夕法尼亚大学沃顿商学院（Wharton School）的经济学学士学位。
Christina Morrison,has served as a director of Invivo Therapeutics Holdings Corp. since June 2016. Since October of 2023, Ms. Morrison has served as Chief Financial Officer of ValenzHealth, a service provider for self-funded health insurance plans, Ms. Morrison served as Chief Financial Officer of Physicians Endoscopy, an ambulatory surgical center management company, from April 2018 to April 2023. Prior to that Ms. Morrison served as the Senior Vice President of Finance of Aramark, a publicly traded foodservice, facilities and uniform services provider, from June 2013 until July 2016. Prior to joining Aramark, Ms. Morrison was Senior Vice President of Business and Financial Planning at Merck & Co., Inc., a publicly traded pharmaceutical company, from November 2009 to June 2013. Before that, Ms. Morrison spent five years at Wyeth Pharmaceuticals, a publicly traded pharmaceutical company, serving in a number of leadership roles including Senior Vice President and Chief Financial Officer of the pharmaceutical division. Ms. Morrison holds an M.B.A. from the Tuck School of Business at Dartmouth College and a B.S. in Economics from the Wharton School at the University of Pennsylvania. - Christina Morrison自2016年6月起担任公司董事。莫里森女士自2018年4月起担任门诊手术中心管理公司Physicians Endoscope的首席财务官。在此之前，Morrison女士于2013年6月至2016年7月担任Aramark（一家公开上市的食品服务，设施和制服服务提供商）财务高级副总裁。在加入ARAMARK之前，莫里森女士于2009年11月至2013年6月担任默克制药公司（一家公开上市的制药公司）业务和财务规划高级副总裁。在此之前，Morrison女士在惠氏制药公司（Wyeth Pharmaceuticals）工作了五年，该公司是一家公开上市的制药公司，担任过多个领导职务，包括制药部门的高级副总裁和首席财务官。Morrison女士拥有达特茅斯学院塔克商学院（Tuck School of Business at Dartmouth College）的工商管理硕士学位和宾夕法尼亚大学沃顿商学院（Wharton School）的经济学学士学位。
- Christina Morrison,has served as a director of Invivo Therapeutics Holdings Corp. since June 2016. Since October of 2023, Ms. Morrison has served as Chief Financial Officer of ValenzHealth, a service provider for self-funded health insurance plans, Ms. Morrison served as Chief Financial Officer of Physicians Endoscopy, an ambulatory surgical center management company, from April 2018 to April 2023. Prior to that Ms. Morrison served as the Senior Vice President of Finance of Aramark, a publicly traded foodservice, facilities and uniform services provider, from June 2013 until July 2016. Prior to joining Aramark, Ms. Morrison was Senior Vice President of Business and Financial Planning at Merck & Co., Inc., a publicly traded pharmaceutical company, from November 2009 to June 2013. Before that, Ms. Morrison spent five years at Wyeth Pharmaceuticals, a publicly traded pharmaceutical company, serving in a number of leadership roles including Senior Vice President and Chief Financial Officer of the pharmaceutical division. Ms. Morrison holds an M.B.A. from the Tuck School of Business at Dartmouth College and a B.S. in Economics from the Wharton School at the University of Pennsylvania.
- Richard Toselli
-
Richard Toselli自2018年2月起担任我们的总裁兼首席执行官兼董事。在被任命为总裁兼首席执行官和董事之前，Toselli博士于2017年12月至2018年2月担任我们的代理首席执行官。自2017年7月起，Toselli博士还担任我们的首席医疗官。在加入公司之前，Toselli博士于2016年6月至2017年3月担任医疗器械公司Cochlear Limited的首席医疗官。在此之前，托塞利博士于2012年7月至2016年6月在赛诺菲（Sanofi）任职，该公司是一家制药公司，职责不断增加，包括负责全球医疗事务的Vice President——免疫学和炎症，生物制剂部门；全球医疗事务Vice President兼生物外科发现绩效股股长；生物外科全球医疗事务Vice President。在加入赛诺菲（Sanofi）之前，他曾担任医疗设备公司柯惠公共有限公司（Nomura）（现为美敦力有限公司）的首席医疗/技术官，此前，他曾在医疗设备公司强生公司担任设备行业循证医学Vice President，医药及消费品包装制品制造公司。在此之前，Toselli博士曾在DePuy Synthes Spine，Inc.担任多个职位，该公司是一家医疗设备公司，包括医疗事务总监、研究与开发全球Vice President以及临床证据和对外关系全球Vice President。Toselli博士持有普罗维登斯学院（Providence College）的文学学士学位，布朗大学（Brown University）的医学学位，以及北卡罗来纳州肯南-弗拉格勒商学院（the UNC’；s Kenan-Flagler Business School）的工商管理硕士学位。Toselli博士是董事会认证的神经外科医生。
Richard Toselli,has served as Invivo Therapeutics Holdings Corp. President and Chief Executive Officer and a director since February 2018. Prior to being appointed President and Chief Executive Officer and a director, Dr. Toselli served as Invivo Therapeutics Holdings Corp. Acting Chief Executive Officer from December 2017 to February 2018. Since July 2017, Dr. Toselli has also served as Invivo Therapeutics Holdings Corp. Chief Medical Officer. Before joining the company, Dr. Toselli served as the Chief Medical Officer for Cochlear Limited, a medical device company, from June 2016 until March 2017. Prior to that, Dr. Toselli served at Sanofi, a pharmaceutical company, from July 2012 to June 2016 in various levels of increasing responsibility, including Vice President of Global Medical Affairs—Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Public Limited Company (now Medtronic Public Limited Company), a medical device company, and earlier held the position of Vice President of EvidenceBased Medicine for the device sector at Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturing company. Prior to that, Dr. Toselli held various roles at DePuy Synthes Spine, Inc., a medical device company, including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. Since May of 2022, Dr. Toselli has also served on the Board of SpineX, a private biotechnology company developing neuromodulation devices for neurologic disorders. Dr. Toselli holds a Bachelor of Arts from Providence College, his medical degree from Brown University, and a Master of Business Administration from the UNC's Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon. - Richard Toselli自2018年2月起担任我们的总裁兼首席执行官兼董事。在被任命为总裁兼首席执行官和董事之前，Toselli博士于2017年12月至2018年2月担任我们的代理首席执行官。自2017年7月起，Toselli博士还担任我们的首席医疗官。在加入公司之前，Toselli博士于2016年6月至2017年3月担任医疗器械公司Cochlear Limited的首席医疗官。在此之前，托塞利博士于2012年7月至2016年6月在赛诺菲（Sanofi）任职，该公司是一家制药公司，职责不断增加，包括负责全球医疗事务的Vice President——免疫学和炎症，生物制剂部门；全球医疗事务Vice President兼生物外科发现绩效股股长；生物外科全球医疗事务Vice President。在加入赛诺菲（Sanofi）之前，他曾担任医疗设备公司柯惠公共有限公司（Nomura）（现为美敦力有限公司）的首席医疗/技术官，此前，他曾在医疗设备公司强生公司担任设备行业循证医学Vice President，医药及消费品包装制品制造公司。在此之前，Toselli博士曾在DePuy Synthes Spine，Inc.担任多个职位，该公司是一家医疗设备公司，包括医疗事务总监、研究与开发全球Vice President以及临床证据和对外关系全球Vice President。Toselli博士持有普罗维登斯学院（Providence College）的文学学士学位，布朗大学（Brown University）的医学学位，以及北卡罗来纳州肯南-弗拉格勒商学院（the UNC’；s Kenan-Flagler Business School）的工商管理硕士学位。Toselli博士是董事会认证的神经外科医生。
- Richard Toselli,has served as Invivo Therapeutics Holdings Corp. President and Chief Executive Officer and a director since February 2018. Prior to being appointed President and Chief Executive Officer and a director, Dr. Toselli served as Invivo Therapeutics Holdings Corp. Acting Chief Executive Officer from December 2017 to February 2018. Since July 2017, Dr. Toselli has also served as Invivo Therapeutics Holdings Corp. Chief Medical Officer. Before joining the company, Dr. Toselli served as the Chief Medical Officer for Cochlear Limited, a medical device company, from June 2016 until March 2017. Prior to that, Dr. Toselli served at Sanofi, a pharmaceutical company, from July 2012 to June 2016 in various levels of increasing responsibility, including Vice President of Global Medical Affairs—Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Public Limited Company (now Medtronic Public Limited Company), a medical device company, and earlier held the position of Vice President of EvidenceBased Medicine for the device sector at Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturing company. Prior to that, Dr. Toselli held various roles at DePuy Synthes Spine, Inc., a medical device company, including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. Since May of 2022, Dr. Toselli has also served on the Board of SpineX, a private biotechnology company developing neuromodulation devices for neurologic disorders. Dr. Toselli holds a Bachelor of Arts from Providence College, his medical degree from Brown University, and a Master of Business Administration from the UNC's Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon.
- Robert J. Rosenthal
-
Robert J. Rosenthal， 他是IMI Intelligent Medical Implants公司（医疗技术公司）的主席兼首席执行官（从2010年到2012年）。他曾担任Magellan Biosciences公司（临床诊断和生命科学研究的工具的供应商）的总裁兼首席执行官、TekCel公司（生命科学研究工具的供应商）的总裁和首席执行官、Boston Life Sciences公司（诊断和治疗开发公司）的总裁兼首席执行官（从2002年到2003年）、Magellan Discovery Technologies公司（一个生命科学的收购公司）的总裁兼首席执行官（从2001年到2002年）、Perkin Elmer Corporation的高级副总裁及其仪表部门的总裁（从1999年到2000年），以及Thermo Optek Corporation的多种执行职务（从1995年到1999年）。
Robert J. Rosenthal,has been a director of Invivo Therapeutics Holdings Corp. since November 2019. Dr. Rosenthal currently serves as Chairman of the Board of Directors of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2019 he also served as Chief Executive Officer. Dr. Rosenthal also currently serves as a director of the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2015, and as Chairman of Care Everywhere, a private healthcare IT and medical device provider, since April of 2022. Dr. Rosenthal previously served from 2007 to May of 2022 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of its Board of Directors since May 2016. Since 2013, he has also served as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company. Since 1995, Dr. Rosenthal previously served in a variety of senior management positions with companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal holds a Ph.D. from Emory University and a Master of Science degree from the State University of New York. - Robert J. Rosenthal， 他是IMI Intelligent Medical Implants公司（医疗技术公司）的主席兼首席执行官（从2010年到2012年）。他曾担任Magellan Biosciences公司（临床诊断和生命科学研究的工具的供应商）的总裁兼首席执行官、TekCel公司（生命科学研究工具的供应商）的总裁和首席执行官、Boston Life Sciences公司（诊断和治疗开发公司）的总裁兼首席执行官（从2002年到2003年）、Magellan Discovery Technologies公司（一个生命科学的收购公司）的总裁兼首席执行官（从2001年到2002年）、Perkin Elmer Corporation的高级副总裁及其仪表部门的总裁（从1999年到2000年），以及Thermo Optek Corporation的多种执行职务（从1995年到1999年）。
- Robert J. Rosenthal,has been a director of Invivo Therapeutics Holdings Corp. since November 2019. Dr. Rosenthal currently serves as Chairman of the Board of Directors of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2019 he also served as Chief Executive Officer. Dr. Rosenthal also currently serves as a director of the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2015, and as Chairman of Care Everywhere, a private healthcare IT and medical device provider, since April of 2022. Dr. Rosenthal previously served from 2007 to May of 2022 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of its Board of Directors since May 2016. Since 2013, he has also served as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company. Since 1995, Dr. Rosenthal previously served in a variety of senior management positions with companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal holds a Ph.D. from Emory University and a Master of Science degree from the State University of New York.
高管简历
中英对照 | 中文 | 英文- Richard Christopher
Richard Christopher于2019年1月被任命为我们的首席财务官。此前，克里斯托弗先生于2016年12月至2019年1月担任iCAD，Inc.首席财务官。iCAD，Inc.是一家纳斯达克上市公司，专注于癌症的早期识别和治疗的疗法和解决方案。在iCAD，Inc.之前，Christopher先生于2014年3月至2016年12月担任Caliber Imaging&Diagnostics，Inc.的首席财务官，并于2015年10月至2016年12月担任首席运营官，该公司是一家专注于癌症检测成像解决方案的医疗技术公司，主要应用于皮肤科。在加入Caliber之前，Christopher先生从2000年开始在DusaPharmaceuticals，Inc.担任多个职责递增的职位，该公司是一家纳斯达克上市的皮肤科公司，专注于癌前皮肤病变的治疗，从2005年1月到2013年4月被Sun Pharmaceuticals Industries Ltd收购和整合，他最终担任首席财务官。Christopher先生拥有萨福克大学（Suffolk University）会计学理学硕士学位和宾利大学（Bentley University）金融学理学学士学位。
Richard Christopher joined Lexaria on Augt 31, 2024 to succeed Christopher Bunka as CEO, utilizing his extensive experience with pharmaceutical and medical device companies to further assist with the transition of Lexaria into the pharmaceutical sector. He was the Chief Financial Officer of InVivo Therapeutics Holdings Corp. ("InVivo") from 2019 to 2024. InVivo Therapeutics was a pioneering biomaterials and biotechnology company with a foc on the treatment of spinal cord injuries. Its goal was to develop and commercialize groundbreaking technologies and treatments for spinal cord injury (SCI). At the core of InVivo's technology portfolio was the Neuro Spinal Scaffold a novel and proprietary biomaterial that is implanted into the epicenter of the injury to modulate the healing environment and serve as a support for neuroregeneration. As the Neuro Spinal Scaffold failed to advance through clinical trials, InVivo delisted from the Nasdaq Stock Market around March 20, 2024.- Richard Christopher于2019年1月被任命为我们的首席财务官。此前，克里斯托弗先生于2016年12月至2019年1月担任iCAD，Inc.首席财务官。iCAD，Inc.是一家纳斯达克上市公司，专注于癌症的早期识别和治疗的疗法和解决方案。在iCAD，Inc.之前，Christopher先生于2014年3月至2016年12月担任Caliber Imaging&Diagnostics，Inc.的首席财务官，并于2015年10月至2016年12月担任首席运营官，该公司是一家专注于癌症检测成像解决方案的医疗技术公司，主要应用于皮肤科。在加入Caliber之前，Christopher先生从2000年开始在DusaPharmaceuticals，Inc.担任多个职责递增的职位，该公司是一家纳斯达克上市的皮肤科公司，专注于癌前皮肤病变的治疗，从2005年1月到2013年4月被Sun Pharmaceuticals Industries Ltd收购和整合，他最终担任首席财务官。Christopher先生拥有萨福克大学（Suffolk University）会计学理学硕士学位和宾利大学（Bentley University）金融学理学学士学位。
- Richard Christopher joined Lexaria on Augt 31, 2024 to succeed Christopher Bunka as CEO, utilizing his extensive experience with pharmaceutical and medical device companies to further assist with the transition of Lexaria into the pharmaceutical sector. He was the Chief Financial Officer of InVivo Therapeutics Holdings Corp. ("InVivo") from 2019 to 2024. InVivo Therapeutics was a pioneering biomaterials and biotechnology company with a foc on the treatment of spinal cord injuries. Its goal was to develop and commercialize groundbreaking technologies and treatments for spinal cord injury (SCI). At the core of InVivo's technology portfolio was the Neuro Spinal Scaffold a novel and proprietary biomaterial that is implanted into the epicenter of the injury to modulate the healing environment and serve as a support for neuroregeneration. As the Neuro Spinal Scaffold failed to advance through clinical trials, InVivo delisted from the Nasdaq Stock Market around March 20, 2024.
- Richard Toselli
Richard Toselli自2018年2月起担任我们的总裁兼首席执行官兼董事。在被任命为总裁兼首席执行官和董事之前，Toselli博士于2017年12月至2018年2月担任我们的代理首席执行官。自2017年7月起，Toselli博士还担任我们的首席医疗官。在加入公司之前，Toselli博士于2016年6月至2017年3月担任医疗器械公司Cochlear Limited的首席医疗官。在此之前，托塞利博士于2012年7月至2016年6月在赛诺菲（Sanofi）任职，该公司是一家制药公司，职责不断增加，包括负责全球医疗事务的Vice President——免疫学和炎症，生物制剂部门；全球医疗事务Vice President兼生物外科发现绩效股股长；生物外科全球医疗事务Vice President。在加入赛诺菲（Sanofi）之前，他曾担任医疗设备公司柯惠公共有限公司（Nomura）（现为美敦力有限公司）的首席医疗/技术官，此前，他曾在医疗设备公司强生公司担任设备行业循证医学Vice President，医药及消费品包装制品制造公司。在此之前，Toselli博士曾在DePuy Synthes Spine，Inc.担任多个职位，该公司是一家医疗设备公司，包括医疗事务总监、研究与开发全球Vice President以及临床证据和对外关系全球Vice President。Toselli博士持有普罗维登斯学院（Providence College）的文学学士学位，布朗大学（Brown University）的医学学位，以及北卡罗来纳州肯南-弗拉格勒商学院（the UNC’；s Kenan-Flagler Business School）的工商管理硕士学位。Toselli博士是董事会认证的神经外科医生。
Richard Toselli,has served as Invivo Therapeutics Holdings Corp. President and Chief Executive Officer and a director since February 2018. Prior to being appointed President and Chief Executive Officer and a director, Dr. Toselli served as Invivo Therapeutics Holdings Corp. Acting Chief Executive Officer from December 2017 to February 2018. Since July 2017, Dr. Toselli has also served as Invivo Therapeutics Holdings Corp. Chief Medical Officer. Before joining the company, Dr. Toselli served as the Chief Medical Officer for Cochlear Limited, a medical device company, from June 2016 until March 2017. Prior to that, Dr. Toselli served at Sanofi, a pharmaceutical company, from July 2012 to June 2016 in various levels of increasing responsibility, including Vice President of Global Medical Affairs—Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Public Limited Company (now Medtronic Public Limited Company), a medical device company, and earlier held the position of Vice President of EvidenceBased Medicine for the device sector at Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturing company. Prior to that, Dr. Toselli held various roles at DePuy Synthes Spine, Inc., a medical device company, including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. Since May of 2022, Dr. Toselli has also served on the Board of SpineX, a private biotechnology company developing neuromodulation devices for neurologic disorders. Dr. Toselli holds a Bachelor of Arts from Providence College, his medical degree from Brown University, and a Master of Business Administration from the UNC's Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon.- Richard Toselli自2018年2月起担任我们的总裁兼首席执行官兼董事。在被任命为总裁兼首席执行官和董事之前，Toselli博士于2017年12月至2018年2月担任我们的代理首席执行官。自2017年7月起，Toselli博士还担任我们的首席医疗官。在加入公司之前，Toselli博士于2016年6月至2017年3月担任医疗器械公司Cochlear Limited的首席医疗官。在此之前，托塞利博士于2012年7月至2016年6月在赛诺菲（Sanofi）任职，该公司是一家制药公司，职责不断增加，包括负责全球医疗事务的Vice President——免疫学和炎症，生物制剂部门；全球医疗事务Vice President兼生物外科发现绩效股股长；生物外科全球医疗事务Vice President。在加入赛诺菲（Sanofi）之前，他曾担任医疗设备公司柯惠公共有限公司（Nomura）（现为美敦力有限公司）的首席医疗/技术官，此前，他曾在医疗设备公司强生公司担任设备行业循证医学Vice President，医药及消费品包装制品制造公司。在此之前，Toselli博士曾在DePuy Synthes Spine，Inc.担任多个职位，该公司是一家医疗设备公司，包括医疗事务总监、研究与开发全球Vice President以及临床证据和对外关系全球Vice President。Toselli博士持有普罗维登斯学院（Providence College）的文学学士学位，布朗大学（Brown University）的医学学位，以及北卡罗来纳州肯南-弗拉格勒商学院（the UNC’；s Kenan-Flagler Business School）的工商管理硕士学位。Toselli博士是董事会认证的神经外科医生。
- Richard Toselli,has served as Invivo Therapeutics Holdings Corp. President and Chief Executive Officer and a director since February 2018. Prior to being appointed President and Chief Executive Officer and a director, Dr. Toselli served as Invivo Therapeutics Holdings Corp. Acting Chief Executive Officer from December 2017 to February 2018. Since July 2017, Dr. Toselli has also served as Invivo Therapeutics Holdings Corp. Chief Medical Officer. Before joining the company, Dr. Toselli served as the Chief Medical Officer for Cochlear Limited, a medical device company, from June 2016 until March 2017. Prior to that, Dr. Toselli served at Sanofi, a pharmaceutical company, from July 2012 to June 2016 in various levels of increasing responsibility, including Vice President of Global Medical Affairs—Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Public Limited Company (now Medtronic Public Limited Company), a medical device company, and earlier held the position of Vice President of EvidenceBased Medicine for the device sector at Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturing company. Prior to that, Dr. Toselli held various roles at DePuy Synthes Spine, Inc., a medical device company, including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. Since May of 2022, Dr. Toselli has also served on the Board of SpineX, a private biotechnology company developing neuromodulation devices for neurologic disorders. Dr. Toselli holds a Bachelor of Arts from Providence College, his medical degree from Brown University, and a Master of Business Administration from the UNC's Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon.
- Heather Hamel
Heather Hamel，2022年7月被任命为Invivo治疗控股公司首席法务官和总法律顾问。在此任命之前，Hamel女士于2020年8月至2022年7月担任Invivo治疗控股公司法律事务和业务发展副总裁。在担任此职位之前，Hamel女士于2017年7月至2020年8月担任Invivo治疗控股公司法律事务和业务发展总监。在加入Invivo治疗控股公司公司之前，Hamel女士曾在艺康公司工作，负责监督各种法律事务，包括知识产权战略、专利起诉和诉讼管理以及PLR IP，Inc.，在那里她负责全球知识产权许可和一系列资产的合作。哈默尔女士还担任过几家早期制药公司的外部法律顾问。Hamel女士拥有威斯康星大学Stevens Point分校的生物化学和化学学士学位、William Mitchell法学院的法学博士学位以及哈佛大学一般管理、推广研究的文科硕士学位。
Heather Hamel,was appointed as Invivo Therapeutics Holdings Corp. Chief Legal Officer and General Counsel in July 2022. Prior to this appointment, Ms. Hamel served as Invivo Therapeutics Holdings Corp. Vice President of Legal Affairs and Business Development from August 2020 through July 2022. Prior to this position, Ms. Hamel served as Invivo Therapeutics Holdings Corp. Director of Legal Affairs and Business Development from July 2017 through August 2020. Before joining Invivo Therapeutics Holdings Corp. Company, Ms. Hamel worked at Ecolab, Inc., where she oversaw a variety of legal matters including intellectual property strategy, patent prosecution and litigation management and PLR IP, Inc., where she was responsible for global intellectual property licensing and partnering across a range of assets. Ms. Hamel has also served as an external legal advisor to several early-stage pharmaceutical companies. Ms. Hamel holds B.S. degrees in biochemistry and chemistry from the University of Wisconsin at Stevens Point, a J.D from William Mitchell College of Law, and a Master of Liberal Arts degree in general management, extension studies from Harvard University.- Heather Hamel，2022年7月被任命为Invivo治疗控股公司首席法务官和总法律顾问。在此任命之前，Hamel女士于2020年8月至2022年7月担任Invivo治疗控股公司法律事务和业务发展副总裁。在担任此职位之前，Hamel女士于2017年7月至2020年8月担任Invivo治疗控股公司法律事务和业务发展总监。在加入Invivo治疗控股公司公司之前，Hamel女士曾在艺康公司工作，负责监督各种法律事务，包括知识产权战略、专利起诉和诉讼管理以及PLR IP，Inc.，在那里她负责全球知识产权许可和一系列资产的合作。哈默尔女士还担任过几家早期制药公司的外部法律顾问。Hamel女士拥有威斯康星大学Stevens Point分校的生物化学和化学学士学位、William Mitchell法学院的法学博士学位以及哈佛大学一般管理、推广研究的文科硕士学位。
- Heather Hamel,was appointed as Invivo Therapeutics Holdings Corp. Chief Legal Officer and General Counsel in July 2022. Prior to this appointment, Ms. Hamel served as Invivo Therapeutics Holdings Corp. Vice President of Legal Affairs and Business Development from August 2020 through July 2022. Prior to this position, Ms. Hamel served as Invivo Therapeutics Holdings Corp. Director of Legal Affairs and Business Development from July 2017 through August 2020. Before joining Invivo Therapeutics Holdings Corp. Company, Ms. Hamel worked at Ecolab, Inc., where she oversaw a variety of legal matters including intellectual property strategy, patent prosecution and litigation management and PLR IP, Inc., where she was responsible for global intellectual property licensing and partnering across a range of assets. Ms. Hamel has also served as an external legal advisor to several early-stage pharmaceutical companies. Ms. Hamel holds B.S. degrees in biochemistry and chemistry from the University of Wisconsin at Stevens Point, a J.D from William Mitchell College of Law, and a Master of Liberal Arts degree in general management, extension studies from Harvard University.